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Abstract
Background: Cell penetrating peptides (CPPs) as one class of non-viral vectors, have been widely explored as a
delivery tool due to their cell-penetrating capability with low cytotoxicity. However, CPPs have reported to have
low gene transfection efficiency mainly due to the fact that DNA is larger than other biomolecules. On the other
hand, the conventional linear CPPs are unstable for constructing the DNA complexes with it. Thus, here we
designed a branched CPP using disulfide bridges based on the linear TAT peptide, to enhance the gene delivery
efficiency in a better way.
Results: The branched TAT (BTAT) was synthesized by the DMSO oxidation method and showed high-molecular-
weight about 294 kDa. The resulting BTAT was complexed with plasmid green fluorescence protein (pGFP) gene
at various N/P ratios. The gene transfection efficiency was assessed on HeLa cells after treating with BTAT/pGFP
complexes, showed high gene transfection efficiency as conformed by flowcytometry followed by confocal laser
scanning microscopy (CLSM) visualization.
Conclusion: The novel BTAT/pGFP complex exhibited significantly higher stability and redox cleavability by reducing
agent. In addition, BTAT showed higher transfection efficiency approximately 40-fold than those of the TAT and mTAT
complexes. Our primary experiments demonstrated the potential of BTAT as a suitable candidate for gene delivery and
it could be applied for various types of gene delivery platforms.
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sorting; FBS, Fetal bovine serum; GSH, Glutathione; HEPES, 2-[4-(2-hydroxyethyl) piperazin-1-yl] ethanesulfonic
acid; mTAT, Modified TAT; PEI, Poly (ethyleneimine), CLSM, confocal laser scanning microscope; pGFP, Plasmid
green fluorescence protein; TEM, Transmission electron microscopy
Background
Gene therapy is a powerful tool with the potential to in-
hibit the deleterious effects of malicious genes by insert-
ing corrected/normal genes into the genome to treat the
disease. Precisely, it could treat the disease by delivering
specific nucleic acid into the target cells instead of drugs
[1]. The concept of the gene therapy has been well
known since 1970s [2] and it showed improved
therapeutic effects in the various genetic diseases [3–6].
A variety of experimental results showed the benefits of
gene therapy and further studies have been investigated
to enhance the therapeutic effects by overcoming bio-
logical barriers such as immune response, high cellular
toxicity and low transfection efficiency. To improve gene
delivery capability with low cytotoxicity, various non-
viral delivery vectors have been used such as liposome,
cell-penetrating peptide (CPP) and cationic polymers
[7–9]. Among the non-viral gene delivery tools, peptide-
based vehicles have been widely used due to their bio-
compatibility and biodegradability [10–15].
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Cell-penetrating peptides (CPPs) are representative
peptide-based carriers and composed of short amino acid
sequences less than 40. The CPPs possess positive charge
because it consists of positively charged amino acids such
as lysine and arginine. Being cationic in nature, CPPs
could easily get inside the cells via various endocytosis
mechanisms mediated by clathrin, and clathrin-
independent endocytosis etc. [16]. Owing to these unique
properties, the CPPs could interact with the negatively
charged cellular membrane and enter the cells by means
of their cell permeable characteristics without any cyto-
toxicty [16]. For over 20 years, CPP based gene delivery
has been investigated [17–23] to enhance the transfection
efficiency and introduce the targeting capability to the
CPP/DNA complexes. The first CPPs were truncated from
the transduction domain of the HIV-virus, TAT (48–60),
since then it has been widely studied [24].
Although natural CPPs can penetrate into the cells
without toxicity, transfection efficiency is too low to
achieve expected therapeutic effects due to their low-
molecular-weight, unstable linear structure and weak
gene condensation capability. To overcome these draw-
backs, various CPP modifications have been studied by
conjugating with different chemical moieties. The
branched structures are more advantageous than linear
molecules to deliver biomolecules into cells [25]. To
construct a branched structure, linear molecules must
be linked with each other. As one method for linking,
the disulfide bond is a simple and useful bridge for pep-
tide modification because disulfide bridge can be easily
linked by an oxidation method. In addition, the disulfide
link is sensitively cleaved by reducing agents such as
glutathione (GSH) which is overproduced in cytoplasm
of cancer cells compared with normal cells [26]. There-
fore, the branched peptide linked by a disulfide bond
with each other would be degraded in cancer cells under
reducing conditions.
Herein, we designed the branched TAT (BTAT) using
the modified type of TAT (mTAT, Cys-TAT-Cys-TAT-
Cys) which contains cysteine sequences to construct a
disulfide bonds. The thiol groups of the cysteines were
linked with each other in mild oxidation conditions
through dimethyl sulfoxide (DMSO). In the mTAT se-
quences, cysteines were positioned in the middle of the
total sequence as well as the end site. Consequently, we
hypothesize that disulfide bonds will be formed in hori-
zontal and vertical directions as shown in Fig. 1a. The
negatively charged pGFP could easily be complexed
with positively charged branched TAT through electro-
static interactions, enabling better cellular permeability
by means of CPP’s cell-permeable characteristics. The
branched structures would be destroyed under redu-
cing conditions in the cytoplasm of cancer cells, allow-
ing the pGFP to be released as shown in Fig. 1b.
Methods
Materials
Dulbecco’s Modified Eagle’s Medium (DMEM), Fetal Bo-
vine Serum (FBS), Antibiotic Antimycotic Solution (AAS),
Polyethyleneimine (PEI, 25 kDa), Dimethyl Sulfoxide
(DMSO) were purchased from Sigma-Aldrich (MO, USA).
The Plasmids green fluorescence protein (pGFP, 5715 bp)
gene was provided from KRIBB (Daejeon, Korea). The
modified TAT (CYGRKKRRQRRRCYGRKKRRQRRRC)
and TAT (YGRKKRRQRRR) were purchased from Pep-
tron Co. Ltd (Daejeon, Korea). The HeLa (human cervical
carcinoma, ATCC CCL-2) cell line was grown in DMEM
supplemented with 10 % v/v FBS and 1 % v/v AAS. The
cells were incubated in the CO2 incubator with 5 % CO2
at 37 °C for 1 day. The pGFP gene was extracted from E.
coli using plasmid DNA extraction kit (HiSpeed Plasmid
Maxi Kit, QIAGEN, Germany). According to the Maxi kit
protocol, pGFP gene was obtained with high purity >1.8.
Availability of data and materials
1. Plasmids green fluorescence protein (pGFP, 5715 bp)
gene
– The pGFP gene was provided by KRIBB
(Daejeon, Korea) and it is not a raw material.
From plRES2-EGFP, take EGFP by PCR and
clone the vector with using only Nhel at pcDNA
3.1/zeo (+).
2. HeLa cell line
– The HeLa (human cervical cancer, ATCC CCL-2)
cell was purchased from the Korean Collection for
Type Culture (KCTC) (Daejeon, Korea).
The Branched TAT (BTAT) peptide synthesis
To synthesize the branched TAT (BTAT), mTAT
(20 mg) was dissolved in PBS (pH 7.4) and 20 % v/v
DMSO solvent. For the oxidation reactions of thiol
groups of cysteines, mTAT solvent was stirred at the
room temperature for overnight. The BTAT was diluted
in the 10 mM HEPES buffer (pH 7.4) to avoid the extra
reaction. The free mTAT and DMSO were removed by
dialysis (MWCO 10000) for 1 day against distilled water.
The purified BTAT was then obtained by lyophilization.
BTAT was dissolved in distilled water at the concentra-
tions of 0.15, 0.25, 0.5, 0.75 and 1 mg/mL. The absolute-
molecular-weight was then measured by static light scat-
tering (SLS) method using a Zetasizer (Zetasizer-Nano
ZS90, Malvern Instruments, UK). The peptide structures
of TAT, mTAT and BTAT were determined by a CD
spectrometer (Jasco-815, Jasco, Japan).
Formation of pGFP complexes
The TAT/pGFP, mTAT/pGFP, BTAT/pGFP and PEI/
pGFP complexes were prepared by mixing with a pGFP
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(1 μg) at the different N/P ratios and incubated for
30 min at RT. The N/P ratio is calculated as follows: At
N/P =1, BTAT (0.64 μg)/pGFP (1 μg).
Gel retardation assay
To confirm the gene condensation capability of the
BTAT, agarose gel retardation assay was conducted. All
of the samples were prepared by mixing pGFP (0.5 μg)
with the TAT, mTAT, BTAT and PEI at the various N/P
ratios (0.3–8). After 30 min of incubation, each sample
was dyed with Dyne Loading STAR (DYNE BIO, Korea)
at 5:1 % v/v ratio. Agarose gel was prepared by dissolv-
ing the agarose (0.4 mg) in 40 mL of 1X Tris-acetate-
EDTA (TAE) buffer. Each pGFP complex was loaded
into the well of an agarose gel and electrophoresed for
20 min.
To determination of the redox cleavability of BTAT/
pGFP complex, Glutathione (GSH) was added to the
complex solution at a final concentration of 10 mM and
incubated at 37 °C for 4 h.
Size and zeta potential measurement
The pGFP (4 μg) was mixed with TAT, mTAT, BTAT
and PEI at the various N/P ratios. After 30 min incuba-
tion, distilled water was added to each sample to the
total volume of 800 μL. Sizes and zeta potentials were
measured by dynamic light scattering (DLS, Zetasizer-
Nano ZS90, Malvern Instruments, UK).
Morphology analysis of BTAT/pGFP complex
The morphology of complex was determined by trans-
mission electron microscopy (TEM, Tecnai F20 200 kV
microscope, Philips). The BTAT/pGFP complexes were
dropped on the carbon coated mesh grid (200-mesh) for
2 h.
Cell viability test
The HeLa cells were seeded into the 96-well plates at
1 × 104 cells/well and incubated for 24 h. After 1 day,
Opti-MEM containing pGFP (0.25 μg) complexes at the
various N/P ratios were treated into the each well. After
incubation for 24 h, MTT (5 mg/ml in PBS) solution
Fig. 1 Synthesis and schematic illustration of the BTAT/pGFP complex delivery for the gene transfection
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was added to the each well and incubated for 3 h. There-
after, DMSO (100 μL) was added and the absorbance
was measured at 590 nm wavelength through microplate
reader (Multiskan™ Go Microplate Spectrophotometer,
Thermo Co., U.S.A).
Transfection efficiency of pGFP complex
The HeLa cells were seeded into the 24-well plates at
4 × 104 cells/well and incubated for 24 h at 37 °C. The
Hela cells were treated with Opti-MEM (450 μL) con-
taining pGFP (1 μg) with TAT, mTAT and BTAT at an
N/P ratio 4 and incubated for 4 h. The cells washed with
phosphate-buffered saline (PBS) and fresh DMEM sup-
plemented with 10 % v/v FBS and 1 % v/v AAS was
added. The cells were then incubated for 2 days and
medium were removed. After washing with PBS three
times, the cells were detached by trypsin. The transfec-
tion efficiencies were measured by flow cytometry (BD
FACSCalibur, BD Biosciences, USA).
For qualitative analysis, the cell nuclei were stained
with DAPI for 10 min and fixed by 4 % paraformalde-
hyde. The cells were then washed three times with PBS
and mounted on the slide glass. The cellular images
were then analyzed and captured by the confocal laser
scanning microscopy (CLSM, C2+, Nikon, Japan).
Results and discussion
Molecular weight and secondary structure of the branched
TAT (BTAT)
The branched TAT (BTAT) was synthesized via disulfide
bridges using modified type of TAT containing the cyst-
eine residues. After DMSO oxidation, the mTAT solu-
tion was changed to clear gel form, indicative of BTAT
formation. It could be of mTATs in solution linked with
each other by disulfide bonds, allowing structure from
linear to branched one, resulting in gel formation of
BTAT Table 1. After DMSO oxidation, the absolute-
molecular-weight was measured by static light scattering
(SLS) using the various concentrations of BTAT. As
shown in Fig. 2a, the absolute-molecular-weight of
BTAT was calculated approximately 294 kDa. The
molecular weight increased from mTAT (3.4 kDa) up to
86-fold, indicating that the branched structure was suc-
cessfully constructed by disulfide linkages.
The secondary structure of the TAT, mTAT and BTAT
was determined by using the CD spectra. The secondary
structure of the TAT peptide was known as random coil
[27]. As shown in Fig. 2b, CD spectra showed a random
coil structure of TAT. Similarly, mTAT and BTAT also
showed the identical structures, meaning that disulfide
linkages did not affect the secondary structures.
Gel retardation assay
The gene condensation capability of each complex was
analyzed by the gel retardation assay at the various N/P
ratios, as shown in Fig. 3a. In case of the BTAT complex,
the improved binding ability was observed compared with
TAT, mTAT and PEI complexes. The BTAT/pGFP com-
plex was completely retarded at an N/P ratio 1, while TAT
and mTAT were retarded at an N/P ratio 4. These data
suggest that the branched TAT was able to condense the
pGFP at the low N/P ratios. These enhanced gene con-
densation capability could be well explained based on the
structure of BTAT. Being more branched, it would allow
the pGFP to well interact with the positively charged ran-
dom coils of BTAT, enabling improved interaction within
the structures than the other forms.
Particle size and zeta-potential
For effective gene delivery, the CPP/pGFP complexes
should possess small particle size and positive charge. As
shown in Fig. 3b, the size determinations of the complexes
were investigated at the various N/P ratios ranging from 1
to 20. Particle sizes of all complexes reduced with growing
the N/P ratios due to increase of gene condensation cap-
ability. The BTAT could condense pGFP with a diameter
of approximately 300 nm for an N/P raito 1 whereas <
200 nm was obtained for the N/P ratios from 4 to 20.
Similarly, TAT and modified TAT showed the identical
trends at the N/P ratios ranging from 1 to 20. On the
other hand, the PEI which is commercially used transfec-
tion agent exhibited a large particle than the CPP com-
plexes at an N/P ratio 1 with size of > 300 nm.
The zeta-potential value of each CPP/pGFP complex
was measured at the N/P ratios ranging from 1 to 20. As
shown in Fig. 3c, all of the samples showed the similar
trends. The zeta potential values were increased with in-
creasing N/P ratios as it changed from negative to positive
charge except for BTAT. Only the BTAT/pGFP complex
exhibited a positive charge at an N/P ratio 1. According to
the previous reports, the positive charge of complex is es-
sential for penetration into cells by electrostatic inter-
action with negatively charged cellular membrane [16].
Based on these results, although the molecular weight was
much higher than that of PEI, the BTAT/pGFP complex
had reasonable particle size to penetrate into cells.
Table 1 Amino acid sequences, molecular weight and number of amino acids of CPPs
CPPs Amino acid sequences Molecular weight (Da) Number of amino acids
TAT YGRKKRRQRRR 1560 11
mTAT CYGRKKRRQRRRCYGRKKRRQRRRC 3409 25
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Morphology analysis of BTAT/pGFP complex
To confirm the morphology of the BTAT/pGFP com-
plex, the BTAT/pGFP complex was prepared at an N/P
ratio 4. As shown in Fig. 3d, the TEM images showed a
spherical nano-structure for BTAT complexes. Figure 3d
clearly shows that the DNA was mostly encapsulated in
BTAT structure and the BTAT/pGFP particle size was
about 200 nm at an N/P ratio 4. The branched structure
and condensed DNA was well formulated in BTAT/
pGFP as visualized by the TEM image (Fig. 3d).
Fig. 3 a The agarose gel retardation assays and b Particle sizes and c zeta-potential values of the CPP/pGFP complexes at the various N/P ratios.
d TEM images of the BTAT/pGFP complex. e Size change of the BTAT/pGFP complex in water after 10 mM GSH treatment
Fig. 2 Synthesis and characterization of the BTAT. a The absolute molecular weight of the branched TAT (b) The CD spectra determination of the
TAT, modified TAT and branched TAT
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Redox cleavability of BTAT complex
To demonstrate the cleavability of the BTAT linked with
disulfide bonds, the BTAT/pGFP complexes were incu-
bated in 10 mM GSH solution at the various N/P ratios.
The gel retardation assay was then conducted to confirm
whether the DNA could release or not under reducing
environments. As shown in Fig. 3a, the BTAT/pGFP
complex was degraded and the pGFP band moved to
bottom of agarose gel at the N/P ratios ranging from 1
to 6.
In addition, the particle size changes under reduc-
tive conditions were investigated in presence and ab-
sence of GSH. In the presence of GSH, the particle
size significantly increased up to 1000 nm (Fig. 3e).
On the other hand, the average size of the BTAT/
pGFP complex was not changed when dissolved in
the distilled water without 10 mM GSH. These results
showed that the BTAT composed of disulfide bonds
possesses redox cleavability in reductive conditions
and this property could be applied for cancer cell tar-
geting system.
Cell viability test
The cell viability of the CPP/pGFP complexes was deter-
mined by MTT assay in the HeLa cells. As shown in
Fig. 4, all of the CPP/pGFP complexes were shown
more than 80 % cell viability at an N/P ratio of 4,
meaning that all of the complexes were cytocompati-
ble at the lower N/P ratios. The Poly (ethylenimine)
(PEI) was used as a positive control. PEI is a polyca-
tion commonly used as gene transfection agent due
to the high transfection efficiency and its easy
usability. However, the PEI based gene delivery sys-
tems often induce high cytotoxicity problems. In our
study, PEI observed to be cytotoxic as indicated in a
gray bar in the Fig. 4. However the PEI/pGFP com-
plexes were found to be cytocompatible at an N/P ra-
tio 4, while it showed high cytotoxicity at an N/P
ratio of 10. On the other hand, the BTAT/pGFP com-
plex exhibited low toxicity than those of PEI at the
identical N/P ratios. Despite the high concentrations
of BTAT, the BTAT/pGFP complex could show more
than 50 % of the cell viability, while the PEI/pGFP
complexes decreased the cell viability approximately
10 % at the N/P ratios of 15 and 20, indicating the
high cell viability of the BTAT/pGFP complex was
contributed by the effective cleavage of the disulfide
bonds in the reductive environments.
Transfection efficiency of pGFP complex
The proportion of the transfected cells was shown in
Fig. 5a. The HeLa cells were transfected by TAT/pGFP,
mTAT/pGFP and BTAT/pGFP at an N/P ratio 4 and
the proportion of the transfection was approximately
0.7 ± 0.26 %, 0.75 ± 0.25 % and 45.9 ± 1.87 %, respect-
ively. It showed that the BTAT has superior transfec-
tion efficacy compared with conventional CPPs and
PEI. This could be explained based on their branched
networking and high positive charges to condense the
pGFP complexes allowing an effective penetration into
the cells.
To visualize the transfected cells, confocal laser
scanning microscope (CSLM) analysis was conducted.
TAT, mTAT and BTAT were complexed with pGFP at
an N/P ratio 4. The PEI/pGFP complex was prepared
at an N/P ratio 5 as a positive control. As shown in
Fig. 5b, the green fluorescence from HeLa cells indicat-
ing high transfection efficiency of BTAT, whereas neg-
ligible fluorescence was observed with the TAT/pGFP
and mTAT/pGFP complexes. Though, PEI showed
green fluorescence, the BTAT showed significantly
higher mean fluorescence intensity than all other
samples.
Conclusion
In our study, the BTAT has been made successfully to
demonstrate its potential as gene delivery carrier with
improved cytocompatibility than the well explored PEI.
The mTAT peptide was conjugated with each other by
disulfide linkage in horizontal and vertical direction.
Owing to the high charge density of BTAT, it formed a
stable complex with pGFP. The novel BTAT/pGFP com-
plex showed higher transfection efficiency of approxi-
mately 40-fold than those of the TAT and mTAT
complexes. In addition, despite the high positive charge
of BTAT, the BTAT/pGFP complex showed high cell
Fig. 4 Cell viability test. Dose-dependent cytotoxicities of CPP/pGFP
complexes in the HeLa cells
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viability as the disulfide links were degraded in the cyto-
plasm. As we expected, the positively charged BTAT
could penetrate the cells efficiently, with high gene
transfection efficiency. Therefore, the BTAT may act a
powerful tool for gene delivery and has great potential
to apply to any other types of the gene delivery
platforms.
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